A Sanofi supported symposium at EAHAD 2023

Wednesday, February 8, 2023, 11:30-12:45 GMT

Exchange Auditorium, Manchester Central Convention Complex
Manchester, England


Event Information

Join us to learn about the emerging nonfactor therapies, including rebalancing agents, for managing hemophilia.

Hemophilia is incurable, but is manageable, most commonly through factor replacement prophylaxis with purified or recombinant clotting factor concentrates. Although factor replacement may be standard of care, this therapy is still associated with a high health burden and doesn’t always fit patient needs. Nonfactor therapies are in late-stage trials, which utilize multiple mechanisms of action, including treatments designed to inhibit natural anticoagulants to “rebalance” the hemostatic process. Given the rapid evolution of the non-replacement therapies for the management of hemophilia, it is important that clinicians be fully conversant with this emerging group of medications.  


11:15     Doors open and lunch provided

11:30    Welcome and Introduction

11:35    The Balancing Act: What Do We Know?

11:50    Tipping the Scales: The Role of Rebalancing Agents in Achieving Hemostasis

12:10    Finding the Balance: Implications for the Present and Future

12:35    Summary of Key Points and Q and A

12:45    Adjourn

Register to Attend

Faculty Presenters

Ana Boban, MD
Head of Hemophilia Center
University Hospital Centre
Associate Professor of Internal Medicine
School of Medicine of the University of Zagreb
Zagreb, Croatia

Víctor Jiménez Yuste, MD
Head of Hematology
Service at La Paz University Hospital
Group of Coagulopathies and Alterations of Haemostasis, IdiPAZ
Associate Professor of Hematology
Autonomous University of Madrid
Madrid, Spain

Carmen Escuriola, MD
Director of the Haemophilia Centre Rhein Main
HZRM, Frankfurt-Mörfelden
Mörfelden-Walldorf, Germany

The France Foundation

A ACCME Accredited provider.

The France Foundation ©

Chandler Building, 84 Lyme Street, Old Lyme, CT USA